학술논문
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Document Type
Article
Author
Source
In Kidney International Reports March 2022 7(3):436-443
Subject
Language
ISSN
2468-0249